Angiogenesis: regulators and clinical applications
- 6 February 2001
- journal article
- review article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 61 (3), 253-270
- https://doi.org/10.1016/s0006-2952(00)00529-3
Abstract
No abstract availableThis publication has 180 references indexed in Scilit:
- Angiogenesis: How a Tumor Adapts to HypoxiaBiochemical and Biophysical Research Communications, 1999
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaThe New England Journal of Medicine, 1999
- uPA, uPAR, PAI-I: Key intersection of proteolytic, adhesive and chemotacfic highways?Immunology Today, 1997
- Role of soluble mediators in angiogenesisEuropean Journal of Cancer, 1996
- Inhibition of fibroblast growth factorsBreast Cancer Research and Treatment, 1996
- Failure of blood-island formation and vasculogenesis in Flk-1-deficient miceNature, 1995
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences of the United States of America, 1994
- Transforming growth factor‐β1 stimulates macrophage urokinase expression and release of matrix‐bound basic fibroblast growth factorJournal of Cellular Physiology, 1993
- Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitroBiochemical and Biophysical Research Communications, 1992
- Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cellsBiochemical and Biophysical Research Communications, 1991